LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Recursion Pharmaceuticals Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

4.56 7.55

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

4.25

Max

4.63

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-24M

-202M

Pardavimai

10M

15M

Pelnas, tenkantis vienai akcijai

-0.5

Pelno marža

-1,373.259

Darbuotojai

800

EBITDA

-26M

-191M

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

+56.61% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-07

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-431M

1.9B

Ankstesnė atidarymo kaina

-2.99

Ankstesnė uždarymo kaina

4.56

Naujienos nuotaikos

By Acuity

100%

0%

371 / 382 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Recursion Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-05-15 22:52; UTC

Uždarbis
Pagrindinės rinkos jėgos

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

2025-05-15 20:37; UTC

Svarbiausios naujienos
Uždarbis

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

2025-05-16 00:00; UTC

Rinkos pokalbiai

Xero Bull Stays Positive on Cost Outlook -- Market Talk

2025-05-15 23:47; UTC

Rinkos pokalbiai

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

2025-05-15 23:38; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-05-15 23:38; UTC

Rinkos pokalbiai

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

2025-05-15 23:14; UTC

Svarbiausios naujienos

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

2025-05-15 22:46; UTC

Svarbiausios naujienos
Įsigijimai, susijungimai, perėmimai

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

2025-05-15 22:46; UTC

Įsigijimai, susijungimai, perėmimai

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

2025-05-15 22:46; UTC

Įsigijimai, susijungimai, perėmimai

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

2025-05-15 22:46; UTC

Įsigijimai, susijungimai, perėmimai

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

2025-05-15 21:58; UTC

Uždarbis

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

2025-05-15 21:24; UTC

Uždarbis

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

2025-05-15 20:56; UTC

Rinkos pokalbiai

U.S. Spending Downturn Could Lie Ahead -- Market Talk

2025-05-15 20:54; UTC

Rinkos pokalbiai
Uždarbis

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

2025-05-15 20:54; UTC

Uždarbis

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

2025-05-15 20:51; UTC

Uždarbis

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

2025-05-15 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-05-15 20:50; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

2025-05-15 20:50; UTC

Uždarbis

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

2025-05-15 20:47; UTC

Uždarbis

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

2025-05-15 20:47; UTC

Uždarbis

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

2025-05-15 20:47; UTC

Uždarbis

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

2025-05-15 20:47; UTC

Uždarbis

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

2025-05-15 20:37; UTC

Uždarbis

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

2025-05-15 20:37; UTC

Uždarbis

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

2025-05-15 20:37; UTC

Uždarbis

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

2025-05-15 20:37; UTC

Uždarbis

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

2025-05-15 20:26; UTC

Svarbiausios naujienos

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

2025-05-15 20:25; UTC

Uždarbis

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Recursion Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

56.61% į viršų

12 mėnesių prognozė

Vidutinis 6.75 USD  56.61%

Aukščiausias 8 USD

Žemiausias 3 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Recursion Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

5 ratings

1

Pirkti

4

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

4.15 / 4.75Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

371 / 382 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.